Research & Development May 7, 2026 Halozyme and Oruka sign agreement for Hypercon technology By Salong Debbarma Oruka has licensed the Halozyme technology for use with its lead programme, ORKA-001, which is in development to treat psoriasis and related inflammatory conditions, and up to one
Research & Development May 6, 2026 Citius raises $36.5m for Lymphir commercialisation By Salong Debbarma The therapy is approved by the US Food and Drug Administration (FDA) for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) following at least one prior systemic treatment. The
Research & Development May 6, 2026 MSD concludes Terns acquisition to expand CML pipeline By Salong Debbarma Following a successful tender offer and subsequent merger, the companies announced the completion of the transaction, making Terns a wholly owned subsidiary of MSD. The US Food and
Approvals May 5, 2026 Lannett, Lanexa Biologics and Sunshine Lake secure FDA approval for Langlara By Salong Debbarma Langlara is cleared for use in adults and children with type 1 diabetes mellitus (T1DM), as well as adults with type 2 diabetes mellitus (T2DM). The FDA’s decision
Research & Development May 5, 2026 Latus Bio secures $97m in funding to boost gene therapy access By Salong Debbarma The financing includes a $43m extension led by 8VC, with participation from existing investors BioAdvance, Benjamin Franklin Technology Partners, DCVC Bio, Gaingels, Hatch BioFund and Modi Ventures. New
Approvals May 4, 2026 Arrowhead’s Redemplo secures Australian TGA approval for FCS therapy By Salong Debbarma The therapy is approved as an add-on to diet, specifically for adults with FCS whose triglyceride levels remain high despite standard triglyceride-lowering treatments. The approval marks an expansion
Production & Sales May 4, 2026 Novo Nordisk to launch Ozempic for type 2 diabetes in US By Salong Debbarma The Ozempic oral pill, approved by the Food and Drug Administration (FDA), offers an option for adults with type 2 diabetes to manage blood sugar and cardiovascular risk
Approvals May 1, 2026 Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation By Salong Debbarma Auvelity is a first-in-class therapy targeting both N-methyl D-aspartate (NMDA) and sigma-1 receptors for this indication. The FDA’s decision is based on results from the Phase III ADVANCE-1
Research & Development May 1, 2026 LEO Pharma to acquire gene therapy company Replay By Salong Debbarma The acquisition aims to strengthen LEO Pharma’s capabilities while leveraging Replay’s high payload herpes simplex virus (HSV) delivery vector. It is set to expand LEO Pharma’s pipeline in
Research & Development April 30, 2026 Ray Therapeutics receives EMA PRIME status for gene therapy By Salong Debbarma The designation recognises the potential of RTx-015 to address significant unmet medical needs in patients with severe retinal degeneration. It advances the therapy’s regulatory support following a regenerative